tailieunhanh - Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often shortlived due to the development of acquired resistance. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN